Antiphospholipid Antibodies and Syndrome

Message from the Guest Editor

Dear Colleagues,

Antiphospholipid syndrome (APS) is an autoimmune disorder caused by antiphospholipid antibodies. It was characterized by excessive clotting of blood and/or certain complications of pregnancy (premature miscarriages, unexplained fetal death, or premature birth) and the presence of antiphospholipid antibodies (such as anti-cardiolipin antibodies or lupus anticoagulant) in the blood. Fifty percent of people with lupus have APS. The exact pathogenesis of APS is inadequately understood, so no specific treatment is available.

This Special Issue of Antibodies focuses on the symptoms, pathogenesis, diagnosis, clinical manifestation, therapy of APS, the new research development of antiphospholipid antibodies, and all the other aspects of APS.

Prof. Dr. Ricard Cervera
Guest Editor
Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: Indexed in the Emerging Sources Citation Index (ESCI - Web of Science), EMBASE (Elsevier) and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 14.1 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Antibodies
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

antibodies@mdpi.com